



# Pitfalls in Living Donor Renal Transplantation (LDRT)

Ferdinand Mühlbacher

V. Nephrology Congress in Bosnia  
and Herzegovina


Tuzla, 17 – 20. October 2019

# Life Kidney Donation


## Many advantages

- Short waiting time for patients - Perfect timing
- Scheduled daytime procedure - Best available team
- HLA irrelevant (negative Crossmatch)
- Organ Quality known in advance
- Possible against ABO barrier
- Paired Donation Possible
- Exceptional cases possible (i.e. identical twins)
- Superior results compared to deceased donation

# Kidney only transplant patient survival rates stratified by Donor Deceased vs Living. Transplants: 01.01.2000 to 31.12.2013




# Kidney only transplant graft survival rates stratified by Donor Deceased vs Living. Transplants: 01.01.2000 to 31.12.2013



- Deceased [N=35675]  
- Living [N=11072]

HLA irrelevant in LRD

# LRD vs. LURD vs. DDD



Terasaki P. et. al.: NEJM 333:6, 1995

# Benefits in Life Donation

## Donor

- Biological Benefit: 0
  - Only Risk
- Psychological Benefit:

## Recipient

- Outcomes: Patient and Graft survival much better compared to DDRT

# Pitfalls, Downsides in LDRT

## Pitfalls

- Donor risk
  - Perioperative Mortality
  - Life time expectancy
  - Risk of ESRD
- Interdependance of Donor to Recipient:
  - Act of love ..... court case

## LDRT as an exclusive Organ source

- Insufficient Organ availability
- Unability of
  - repeated RT,
  - VCA and other Organs

# Just One Negative Example



**Mirror** **LIFESTYLE**  
Going out? Staying in? Start here

FRONT PAGE NEWS SPORT 3AM TV **LIFESTYLE** MONEY PLAY OPINION Search

[Lifestyle](#) · [Organisation](#)


## I donated a kidney to my husband then he dumped me - now I want it back



# Donor Risk Information

- We, and many others explained to the potential donor:
  - Minimal mortality risk
  - No reduction in life expectancy
  - No increases risk of ESRD

# Life Donors Live Longer




# 90 Days Mortality

Author		Donors	FU	Mortality 90 days	Complications Clavien ≥3
Fehrman-Ekholm I. et.al.	Transplantation 1997, 64:976-8	1112	20	0	
Segev D.L et. al	JAMA, March 10, 2010—Vol 303, No. 10 959	80347	6,3	25= 0,003%	
Mjøen G. et. al	Kidney International (2014) 86, 162–167	1901	15,1	0	
Burkhalter F. et. al	Swiss Medical Weekly, 2017; 147 w 14497	1649		0	34 (2,1%)
Vienna	unpublished	1477	13,5	0	

# Selection Bias !

- Fehrman-Ekholm compared Kidney Donors with the “General Population”
- Kidney Donors are a healthy selection of the population.
- Kidney Donors have to be matched with a population of the same risk factors:


# Mortality Risk LD vs HND



**Figure 2 | Cumulative mortality risk in kidney donors and controls, adjusted for year of donation. Controls are matched to donors for age, sex, systolic blood pressure, body mass index, and smoking status.**

# Risk of ESRD, LD vs.HND vs.USND

Muzaale JAMA 2014, 311:579-86






No. at risk

Unscreened nondonor	1296	18436	36272	40863	26982	7990	647
Live donor	1143	13144	22647	22944	12151	2575	218
Healthy nondonor	1306	18487	36397	40961	28358	9011	870

# ESDR Risk by Race/Ethnicity

**B** Cumulative incidence of end-stage renal disease by race/ethnicity




No. at risk

Live donors	12387	7910	2887
Nondonors	12387	12256	12093


Live donors	12061	6989	2452
Nondonors	12061	11957	11818

Live donors	71769	44080	16234
Nondonors	71769	71209	70288


# ESRD Risk by Age, Gender, Relationship, Period,




No. at risk	Age, y					
≥60	4039	2858	1967	1223	656	244
50-59	16840	12881	9241	5887	3015	1101
40-49	28994	23621	17929	11728	6261	2549
18-39	46344	38227	29842	20393	11641	4887



No. at risk	Race					
Black						
Men	5330	4409	3449	2247	1238	470
Women	7057	5773	4461	2968	1649	680
White						
Men	28941	23689	18120	12206	6744	2784
Women	42828	34266	25960	17278	9490	3886



No. at risk	Relationship					
Related	64897	54772	43454	30461	17764	7635
Unrelated	31081	22639	15351	8598	3643	1101



No. at Risk	Years					
1994-1997	13290	13263	13220	13135	13020	8781
1998-2001	20667	20620	20539	20426	8550	0
2002-2005	25924	25870	25220	5670	0	0
2006-2009	24827	17834	0	0	0	0
2010-2011	11509					



Author		Donors	FU	ESRD observed	ESRD expected	HR	Control group
Fehrman-Ekholm I. et.al.	Transplantation 1997, 64:976-8 2006, 82:1646-48	1112	20	6 =0,54%	2		
Segev D.L et. al	JAMA, March 10, 2010—Vol 303, No. 10 959	80347	6,3	No difference to controls			9364
Mjøen G. et. al	Kidney International (2014) 86, 162–167	1901	15,1	9 =0,47%	3	11,42	32621
Muzaale AD et.al.	JAMA 2014 311:579-86	96217	7,6	99	36		20024
Vienna unpublished	unpublished	1477	13,5	4 =,27%	2		

# Balance of Risk and Benefit

- There is a very small risk of mortality
- There is a very small risk of decreasing life expectancy
- There is a very small risk of ESRD

These Risks have to be explained and balanced to the psychological benefit !

# Vienna RT Experience

1.1.1965 – 14.10.2019

All Transpalnts	LDRT	
6777	754*)	11,12%

\*) 4 out of 1425 (=0,28%) donors turned into uremia and requiered RRT

# Gender Distribution in LDRT in A

1973 – Aug.2018


Donor	ET Data:	Recipient	ÖDTR:	
F	861	F	480	
M	527	M	945	
Total	1388	Total	1425	
F/M in %	<b>62/38</b>		<b>34/66</b>	

# Vienna RT Experience


1.1.1965 – 30.11.2018

Transplant	#	male	female	Median age
1.	5462	3443	2019	49
2.	902	539	363	43
3.	216	133	83	42
4.	61	38	23	41
5.	15	12	3	44
6.	3	2	1	44
Summary	6659	4167	2492	
		63%	37%	

**KIDNEY TRANSPLANT**  
-all combinations included-  
Annual Rate p.m.p  
2018



**KIDNEY Tx FROM  
LIVING DONORS**  
Annual Rate p.m.p  
2018




# Efficacy of LDRT

2018 (pmp)	A	B	HR	G	H	NL	SLO	F	E	GB	N	BiH 2017
NT	47,0	46,2	43,6	27,8	34,5	58,4	26,7	54,7	71,4	54,7	45,3	4,9
LDRT	8,0	5,0	1,2	6,2	4,6	29,8	1,0	8,3	6,3	15,5	13,6	3,7
%	17,0	10,8	2,8	22,3	13,3	51,0	3,7	15,2	8,8	28,3	30,0	75,5



**How many kidney  
transplants are needed?**

## EUROPEAN UNION DATA



Kidney Transplants	Liver Transplants	Heart Transplants	Lung Transplants	Pancreas Transplants	Small Bowel Transplants	Organs Transplanted
21227 (19.9% LD)	7940 (2.8% LD)	2287	1980	745	42	34221

**11325 ACTUAL DECEASED ORGAN DONORS (9540 DBD and 1785 DCD)**

**2018 data**

**N= 28 COUNTRIES (509.7 million inhabitants)**

# Conclusion

- LDRT still is the best Therapy for ESRD


However

- LDRT has inherent Donor Risk and has a -limited efficacy

Therefore

- Deceased Organ Donation has to be forced to give a chance not only to Kidney patients but also to Heart- Liver- Lung- and VCA Patients in the future.






PCKD  
Nephrectomy 2M  
PD failed  
Hemodialysis  
At 6 M  
5 kg  
LDRT







# Angiography





....7 years later





# The Family

# Mono-ovarian Twins



Bilder mit freundlicher Genehmigung der Familie







# Update 2019 Monoovarian Twins



# Versorgungswirksamkeit der NT



# Waitlist 31.12.2017

	A	B	HR	G	H	NL	SLO
Heart	69	103	35	724	61	107	42
Lung	105	143	-	391	-	178	-
Liver	68	201	107	1086	101	133	18
Kidney	528	849	206	7924	872	673	53
Pancr.	8	26	-	261	29	19	2

# VCA (Vascularized Composite Allografts)




Theo Kelz  
Doppelhand TX 7.3.2000




Isabel Denoir  
Gesichtstransplantation 6.2.2006  
† April 2016 (49a)

# „Cross over“ Transplantation





# „Paired Donation“ Transplantation



# Hand/Arm Transplantation

	Double	Single/Ar m/Hand	Summe	Graft survival
USA	8	13	21	>90%
Europe/Australia	17	13	30	>90%
China	3	9	12	5/12

# Transplantationen in Ö

## Häufigkeit

Organ/System	Häufigkeit in Ö / Jahr
Niere	400
Leber	150
Lunge	120
Herz	70
Pankreas	25
VCA	0-1
Spender	200



Let Us Plant  
a Tree

as a  
Gratitude


to Living and  
Deceased  
Organ  
Donors




# Struktur des Österreichischen Transplantationswesens

Zentrumbasiert, wenig regulatorischer Einfluss (Föderalismus)

- 3 Medizinuniversitäten mit Programmen für alle Organe
- 1 Nierentransplantationsprogramm (in einer nicht akademischen Institution)
- 4 Spenderregionen
- Spenderregion und Patienteneinzugsgebiet weitgehend ident



# Donor- and Tx Frequencies in A






# Themen

- Alterslimit
- GFR Limit
- Follow up Frequency
- Nephrektomieseite
- Open vs Laparoskopie

# History of Renal TX in AKH Vienna



# LDRT Graft Survival 1. Tx by Period

